Needham Rates Viridian Therapeutics (VRDN) buy, $34 Price Target
Needham reaffirmed its buy rating for Viridian Therapeutics with a $34 price target, a 85.08% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Needham rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $34 price target on June 30, 2026.
Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).
VRDN
Viridian Therapeutics, Inc.
Key Points
- Needham reiterated its buy rating on Viridian Therapeutics, Inc. with a $34 price target on June 30, 2026.
- Needham's $34 price target implies 85.08% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
- Viridian's stock traded at $18.79 on Wednesday, with a market cap of $2.03 billion and a 52-week range between $13.18 and $34.29.
- Institutional investors like FMR LLC and BlackRock, Inc. have increased their stakes in Viridian, indicating strong market interest.
Get $VRDN trade alerts by text
We text you when insiders, Congress or big funds trade $VRDN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures
On June 30, 2026, Needham reiterated its buy rating for Viridian Therapeutics, Inc. (NasdaqCM: VRDN), setting a price target of $34. This comes as the company's stock traded at $18.79 on Wednesday.
Needham vs. the S&P 500
Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Viridian Therapeutics
Several institutional investors have shown increased interest in Viridian Therapeutics. FMR LLC grew its holdings by 994,921 shares, bringing its total to approximately 15.4 million shares valued at about $300.8 million, a 6.9% increase. BlackRock, Inc. also increased its position significantly, adding 1,399,552 shares, ending with about 7.8 million shares worth $153.2 million, marking a 21.8% increase. Bellevue Group AG made a substantial addition of 2,367,617 shares, a 54.3% increase, resulting in a total of 6.7 million shares valued at $131.6 million. State Street Corp added 1,206,325 shares, a 34.8% increase, for a total of 4.7 million shares worth $91.4 million. Vanguard Capital Management LLC opened a new position with 4.2 million shares valued at approximately $81.5 million.
Viridian Therapeutics, Inc. Stock Down 16.5%
Shares of Viridian Therapeutics, Inc. traded near $18.79 on Wednesday. The company has a market capitalization of approximately $2.03 billion. It operates in the biotechnology industry, focusing on treatments for serious and rare diseases. The stock's 52-week low is $13.18, with a high of $34.29. It has a 50-day moving average of $16.21 and a 200-day moving average of $24.11. Viridian has a high current ratio of 15.15, indicating strong liquidity, and a quick ratio of 14.71.
$VRDN price target
Viridian Therapeutics, Inc. daily closes and this analyst's $34 target. Not advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Recent insider transactions at Viridian Therapeutics include a purchase by Fairmount Funds Management LLC of 1,176,470 shares at an average price of $17.00 on May 11, 2026. On March 3, 2026, several executives, including Chief Legal Officer Jennifer Tousignant and Chief Operating Officer Thomas Beetham, sold shares at an average price of $30.19.
Analysts Set New Price Targets
On June 30, 2026, several firms maintained their buy ratings for Viridian Therapeutics. RBC Capital set a target of $35, Truist Securities set a $38 target, and Wedbush set a $43 target. Needham also maintained its buy rating with a $34 target. Wells Fargo recently upgraded the stock to a buy with a $31 target on June 29, 2026. The consensus recommendation for Viridian remains a strong buy, with a mean price target of $35.50 based on 16 analyst opinions.
About Viridian Therapeutics
Viridian Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing treatments for serious and rare diseases, including thyroid eye disease and Graves' disease. The company is working on innovative therapies such as Veligrotrug and Elegrobart, which target IGF-1R, and other candidates for autoimmune conditions. Founded in 2010, Viridian is led by CEO Stephen F. Mahoney and employs 252 people.
Bottom Line
Needham's reiterated buy rating and $34 price target for Viridian Therapeutics reflect continued confidence in the company's potential. The stock's recent trading price of $18.79 and strong institutional interest highlight its appeal. Investors keep a close watch on Viridian's progress, especially with its next earnings report expected on August 6, 2026.
Related Filing Alerts
Source: Needham's rating change on $VRDN (Jun 30, 2026). Written by software, not financial advice. How we make alerts